Press release: "Antidote Technologies Drives Patient Recruitment for Three Pivotal COVID-19 Clinical Trials"
With infection rates on the rise once again, effective treatments continue to be a key tool in ending the COVID-19 pandemic
New York, NY (April 20, 2021) — The number of Americans receiving COVID-19 vaccines is rising rapidly, but as restrictions ease and the virus continues to mutate, case numbers are rising as well. With the seven-day average case count hovering just under 70,000 and less than a quarter of Americans fully vaccinated, the need for safe and effective COVID-19 treatments is clear.[1,2] Antidote Technologies, a digital patient engagement company in the clinical trial recruitment space, is dedicated to ensuring successful enrollment for these COVID-19 clinical trials.
In the past three months, Antidote has quickly and effectively delivered more than 20,000 patients across three different COVID-19 clinical trials. The company is aiming for 3,000+ additional participants to deliver on their current contracts, with an eye toward future COVID-19 patient recruitment support as well.
Antidote begins its clinical trial recruitment process with a thorough examination of the patient population needed for a particular trial. Customized digital marketing plans are developed based on in-depth information about the patients needed, and Antidote’s extensive network of advocacy and lab partners is leveraged to assist with reaching patients who might be a fit for each trial. Interested patients land on a digital pre-screener to determine eligibility for each specific trial, and are then able to enroll as appropriate.
“At a time when medical research has never been more important, we’re honored to provide researchers with thoughtful, effective patient recruitment assistance,” said Laurent Schockmel, CEO of Antidote. “Make no mistake: vaccines are critical, but safe and effective methods of treating COVID-19 and preventing severe symptoms and hospitalizations are also key to stemming the pandemic.”
If you are working on a COVID-19 treatment or vaccine trial and would like to discuss your clinical trial recruitment needs, please get in touch.
Antidote is a digital health company on a mission to accelerate medical research. In a world where eighty percent of clinical trials are delayed or closed due to lack of participants, Antidote uses precision recruitment to match the right patients with the right trials. Antidote strikes the right balance between technology and human touch to deliver high-quality patient engagement through the integration of data-driven technologies, digital expertise, deep domain experience, a diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit http://www.antidote.me.
Grace McElroy, Vice President of Marketing and Partnerships
Lisa Conroy, Head of Communications and Demand Generation